Results 131 to 140 of about 178,774 (332)

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis [PDF]

, 2021
I. Monnet, A. Vergnenègre, G. Robinet, H. Bérard, R. Lamy, L. Falchero, S. Vieillot, Roland Schött, Charles Ricordel, Stéphane Chouabe, P. Thomas, Radj Gervais, Anne Madroszyk, S. Abdiche, A Chiappa, Laurent Greillier, C. Decroisette, J.B. Auliac, C. Chouaïd, the GFPC 02-13 (METAL2) investigators   +19 more
openalex   +1 more source

Mechanisms of Resistance to Cancer Immunotherapy: A Host–Tumor Interaction Perspective; A Review Article

Cancer Nexus, EarlyView.
Mechanisms of resistance to cancer immunotherapy from a host–tumor interaction perspective. The central tumor cell is protected by multiple resistance mechanisms, including genetic mutations, epigenetic modifications, and metabolic alterations. The immunosuppressive tumor microenvironment features myeloid‐derived suppressor cells (MDSCs), regulatory T ...
Mohammed Elmujtba Adam Essa, Hamid Noori, Abdelkareem A. Ahmed   +2 more
wiley   +1 more source

Risk of Acute Kidney Injury Associated With Nephrotoxic Burden in Hospitalized Patients: A Scoping Review

Clinical Pharmacology &Therapeutics, EarlyView.
Limited evidence exists synthesizing the risk of acute kidney injury (AKI) associated with the concomitant administration of multiple nephrotoxic drugs, and even less examining the concept of nephrotoxic burden. The objective of this scoping review was to (1) identify definitions of nephrotoxic burden; (2) methods used to quantify (use of calculations)
Wafa Alatawi, Jessica L. Wallace, Dhakrit Rungkitwattanakul, Britney A. Stottlemyer, Tiffany L. Tran, Melanie Manis Reida, Sandra L. Kane‐Gill   +6 more
wiley   +1 more source

An Association between Bevacizumab and Recurrent Posterior Reversible Encephalopathy Syndrome in a Patient Presenting with Deep Vein Thrombosis: A Case Report and Review of the Literature [PDF]

, 2012
Mark A. Lazarus, Stanley Amundson, Rajesh Belani   +2 more
openalex   +1 more source

Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study

Journal for ImmunoTherapy of Cancer
Background Options remain limited for patients requiring later lines of therapy for metastatic non-small cell lung cancer (mNSCLC) due to poor prognosis and potential toxicities.
Enriqueta Felip, Francois Ghiringhelli, Alona Zer, Byoung Chul Cho, Sun Min Lim, Laurent Greillier, Alastair Greystoke, Nuria Pardo, Yaacov R Lawrence, Nedal Al-Sakaff, Hans-Joachim Helms, Hen Prizant, Jan Pintoffl, Farah Louise Lim   +13 more
doaj   +1 more source

Potential neuroprotective and therapeutic agents and their mechanisms for irradiation‐induced brain injury

Ibrain, EarlyView.
In this review, agents such baicalein, troxerutin, epigallocatechin gallate, quercetin, melatonin, valproic acid, lithium, neurosteroid progesterone, as well as minocycline have been implicated as neuroprotective agents for irradiation‐induced neurological deficits. Also, agents such as glucocorticoids, methylphenidate, vitamin E, bisdemethoxycurcumin,
Seidu A. Richard, Vivian Kapio Abem, Sagor Kumar Roy   +2 more
wiley   +1 more source

Bevacizumab reduces PD-L1 Not PD-1 inhibitor-associated pneumonitis in non-small cell lung cancer patients

Cancer Immunology, Immunotherapy
Background Interstitial pneumonitis (IP) is a severe adverse event in patients receiving immunotherapy. Although PD-1/PD-L1 inhibitors and bevacizumab have been widely used in patients with non-small cell lung cancer (NSCLC), the interaction between ...
Linling Wang, Yasi Xu, Yanyan Zhao, Bing Xia, Lucheng Zhu   +4 more
doaj   +1 more source

Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients

International Journal of Cancer, EarlyView.
What's New? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman, Nahal Masrour, Naina Patel, Anna M. Piskorz, Robert Brown, James D. Brenton, Iain A. McNeish, James M. Flanagan   +7 more
wiley   +1 more source

Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab

, 2022
Kei Endo, Hidekatsu Kuroda, Takayoshi Oikawa, Yuma Ito, Tamami Abe, Youhei Kooka, Keisuke Kakisaka, Akio Miyasaka, Tamotsu Sugai, Takayuki Matsumoto   +9 more
openalex   +1 more source

1357P Bevacizumab improved prognosis for advanced EGFR mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy [PDF]

, 2023
Yan Zhou, Jiong Li, Zhilin Li
openalex   +1 more source